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Abstract 
The pretreatment detection of an activating mutation of EGFR is now routinely performed in 
metastatic nonsquamous non-small cell lung cancer (NSCLC). The therapeutic impact of such 
a detection is major, as patients with advanced NSCLC exhibiting a mutation of exon 19 or 21 
will benefit from EGFR-tyrosine kinase inhibitors (TKI). The presence of an EGFR resistance 
mutation, such as T790M in EGFR-TKI-naïve patients, is seldom looked for and is related 
either to a germinal mutation or to somatically mutated subclones. It has a negative 
predictive impact. We present the case of a patient with a lung papillary adenocarcinoma and 
miliary intrapulmonary metastases whose tumor displays a somatic complex heterozygous 
EGFR mutation, combining L858R (exon 21) and a primary resistance mutation T790M (exon 
20), both detected by direct sequencing. © 2014 S. Karger AG, Basel 
Introduction 
The best-characterized mutations of EGFR conferring sensitivity to EGFR-tyrosine ki-
nase inhibitors (TKI) in non-small cell lung cancer (NSCLC) are deletions in exon 19 (Del 19) 
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and point mutations in exon 21 (L858R). Conversely, the most common mutation conferring 
resistance to EGFR-TKI is the exon 20 point mutation (T790M) [1]. 
This T790M mutation is considered the major cause of acquired resistance to EGFR-TKI. 
Primary T790M mutation can also occur at baseline (before TKI treatment) related to a 
germinal mutation or somatically mutated subclones [2]. 
A recent meta-analysis of the predictive role of a pretreatment T790M mutation in 
patients with activating EGFR mutation receiving EGFR-TKI treatment shows that the 
pretreatment T790M mutation has a negative impact on progression-free survival [3]. 
Here, we present the case of a young patient with a primary lung papillary adenocarci-
noma and miliary pulmonary metastases, diagnosed with pretreatment complex EGFR 
mutation combining a heterozygous somatic L858R mutation and T790M mutation. 
Case Description 
A 47-year-old man presented with a history of weight loss from 97 to 92 kg within 1 
month, cough and fatigue. A chest X-ray (fig. 1) showed bilateral multiple micronodules 
described as miliary. The patient had no fever, and his oxygen saturation was 90% (rest time 
without oxygen), improving to 94% under oxygenotherapy (1 liter/min). His performance 
status was 2. Clinical examination was otherwise normal. 
Thoracic CT scan (fig. 2) confirmed miliary metastases and a nodule in the right middle 
lobe and revealed bilateral mediastinal lymph nodes. No other metastasis was found on 
cerebral MRI or abdominopelvic CT scan. Bronchoscopy was macroscopically normal, but 
cytology of bronchoalveolar lavage (BAL) highlighted an adenocarcinoma, which was 
confirmed as papillary subtype by mediastinoscopy. The clinical stage was therefore 
T1aN3M1a. 
Molecular analysis of BAL, containing 30% of tumor cells, by direct sequencing showed 
a somatic complex heterozygous EGFR mutation (fig. 3) composed of L858R mutation in 
exon 21 and T790M mutation in exon 20. T790M was confirmed to be somatic, as it was not 
detected in the paired lymphocytes of the patient. 
We started a treatment with erlotinib (150 mg/day orally). After 15 days, the patient 
returned with worsened dyspnea and an oxygen saturation of 87% with 2 liters/min oxygen. 
He had a grade 3 acneiform rash on the face and the chest. Chest X-ray showed worsening of 
the miliary metastases. Erlotinib was stopped, and chemotherapy with cisplatin-pemetrexed 
and bevacizumab was introduced. After the first cycle of chemotherapy, there was a 
dramatic improvement in oxygen saturation (96% without oxygenotherapy) and regression 
of the miliary metastases. 
Discussion 
EGFR exon 20 insertions account for 4% of EGFR mutations and are associated with a 
lack of sensitivity to EGFR-TKI in preclinical models and in patients [2–4]. Another mutation 
in exon 20 conferring resistance involves a substitution of methionine for threonine at 
position 790 (T790M). This alteration is found as a germ-line variant in 0.5% of never-
smokers with lung adenocarcinoma [5] and may confer genetic susceptibility to lung cancer 
[6]. In fact, EGFR germinal mutations are not looked for in routine practice. 
In the natural history of the disease, T790M mutation could be present in a small subset 
of tumor cells and expand selectively under EGFR-TKI, leading to more than 50% percent of 
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secondary resistance. The frequency of somatic T790M mutation at baseline (before TKI 
treatment) is controversial, and detection depends on the sensitivity of the molecular 
technique. Studies have suggested that pre-existing resistance may be present at a very low 
frequency [6–8]. 
A study found 1 (0.54%) EGFR T790M mutation among 185 NSCLC patients without 
EGFR-TKI treatment, using mutant-enriched PCR analysis, but not confirmed by direct 
sequencing [7]. Others have found frequencies of up to 35% with very high-sensitive 
molecular techniques [9–11]. Usually, T790M could not be detected by direct sequencing 
because of lack of sensitivity. One study reported 2 (0.83%) cases harboring the EGFR 
T790M mutation among 240 patients with EGFR-TKI-naïve lung adenocarcinoma detected 
by sequencing but, contrarily to our case, with both germ-line and somatic T790M mutation 
and without any other EGFR mutation [12]. 
T790M mutation impairs the binding of EGFR-TKI to the EGFR adenosine triphosphate-
binding pocket, and emerging data suggest that T790M change itself may potentiate 
oncogenic activation. Patients whose tumors harbor somatic T790M mutations before 
treatment had a shorter progression-free survival [9–11]. We underline the clinical 
importance of pretreatment T790M mutation detection because the response to EGFR-TKI is 
less certain and could lead to a delay in the introduction of classical platinum-based 
chemotherapy. 
Diffuse, random pulmonary metastases, including miliary metastases, are quite a rare 
presentation in NSCLC and seem to be associated with adenocarcinoma subtype and EGFR 
mutation, suggesting that EGFR-TKI may be the treatment of choice for such patients 
especially in the Asian population [13–15]. A study reported 5 cases of never-smokers with 
lung adenocarcinoma with such a pattern of metastases [16]. In the tumor cells of all 5 
patients, EGFR mutation gene sequencing identified a deletion in exon 19, and all 5 patients 
had a dramatic response to EGFR-TKI. 
No T790M mutation has been reported. In fact, clinical data about patients with lung 
adenocarcinoma harboring EGFR T790M mutations at diagnosis are not described. 
Conclusion 
This case highlights the link between an uncommon radiological presentation of adeno-
carcinoma (miliary pattern) and the clinical importance of the detection of a pretreatment 
(baseline) T790M mutation in NSCLC patients with an activating EGFR mutation. 
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Fig. 1. Chest X-ray showing miliary mottling. 
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Fig. 2. Thoracic CT scan with primary tumor in the middle lobe and miliary metastatic pattern. 
 
 
 
Fig. 3. DNA sequencing electropherograms for DNA obtained a from lung tumor tissue (BAL with 30% 
tumor cells), identifying two heterozygous somatic EGFR mutations [L858R (exon 21) and T790M (exon 
20)] and b from blood, without identifying EGFR mutation. 
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